Washington Entrepreneurial Research Evaluation and Commercialization Hub

华盛顿创业研究评估和商业化中心

• 批准号: 10312529
• 负责人: RODNEY J.Y. HO
• 金额: $ 41.23万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-12-21 至 2023-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10312529
• 关键词: Biomimetics; Biosensor; COVID-19; COVID-19 diagnosis; COVID-19 test; Clinical; Communities; Detection; Development Plans; Devices; Evaluation Research; Funding; Goals; Health; Hospitals; Individual; Infrastructure; Laboratories; Measurable; Outcome; Reagent; Research; Research Personnel; SARS-CoV-2 antigen; Saliva; Salivary; Sampling; Structure; Testing; Time; United States National Institutes of Health; Universities; Viral Antigens; Wait Time; Washington; antigen detection; aptamer; base; biomarker signature; commercialization; innovation; innovative technologies; patient biomarkers; point of care; portability; prevent; prototype; research and development; sound

The overarching goal of the partnership between NIH and the University of Washington (UW) Entrepreneurial Center for Research Evaluation and Commercialization Hub (referred to as WE-REACH) is to facilitate and accelerate the transformation of health research innovations into products. This NIH funded WE-REACH Center is a National Center of REACH in the Northwest region. Two key objectives of the Center are to (1) assist investigators with innovative technologies to establish proof-of-product concept definition (2) facilitating the formation of spinout companies on track to a self-sustaining structure. With well-established expertise, know-how and infrastructure to assist the Research and Development of the following two Covid-19 technical- ready Covid-19 research and develop projects intended to verify proof-of-product concepts with working prototype. (1) Aptamer-based highly sensitive biosensors for salivary COVID-19 antigen detection (Pun) (2) Broad-spectrum detection of VOC and non-VOC biomarkers from patient exhalant using biomimetic multiplexed eNose biosensor for COVID-19 diagnosis (Saikaya) The two technically sound approaches employ by the point-of-care device candidates intend to detect viral antigen in saliva and exhalant biomarker signatures from infected subjects without having to send sample to a centralized facility or a long wait-time for results. WE-REACH will assist the investigators in developing milestone-driven, stage-gated, activity-based project planning and tracking to accelerate proof-of-product concept studies within 2-year of funding. The study results will provide measurable outcomes that are deemed sufficient for upscaling and appropriate for follow-on funding.

NIH和华盛顿大学（UW）之间合作伙伴关系的总体目标 研究评估和商业化中心（简称WE-REACH）是促进和 加快健康研究创新成果向产品的转化。这个NIH资助的WE-REACH 中心是西北地区的REACH国家中心。该中心的两个主要目标是（1） 利用创新技术协助调查人员建立产品验证概念定义（2）促进 组建分拆公司，逐步形成自我维持的结构。凭借成熟的专业知识， 专业知识和基础设施，以协助以下两项Covid-19技术的研发- 准备好Covid-19研究和开发项目，旨在验证产品验证概念， 样机 (1)用于唾液COVID-19抗原检测的基于适体的高灵敏度生物传感器（Pun） (2)使用仿生技术从患者呼出物中广谱检测VOC和非VOC生物标志物 用于COVID-19诊断的多重eNose生物传感器（Saikaya） 床旁设备候选者采用的两种技术上合理的方法旨在检测病毒 唾液中的抗原和来自感染受试者的呼出物生物标志物特征，而不必将样品送至 集中设施或等待结果的时间较长。WE-REACH将协助研究人员开发 以里程碑为导向、分阶段、基于活动的项目规划和跟踪，以加速产品验证 在两年内进行概念研究。研究结果将提供可衡量的结果， 足以扩大规模并适合后续供资。